Kamada CFO Chaime Orlev to Depart After 9 Years; Q2 Revenue Rises 23%
KMDA is trading near its 52-week low of $6.5 (11% above the low).
Summary
CFO Chaime Orlev is leaving Kamada at year-end after a nine-year tenure, with a successor search underway. The departure comes as the company reports strong Q2 results — revenue up 23% to $54.9M and profit of $9.3M — and reaffirms full-year guidance. While the financials were already reported earlier today, the CFO exit is new and introduces leadership uncertainty. The company has a track record of positive operational milestones, including recent FDA lab approval and a $50M plasma supply deal, but a finance chief transition can unsettle investors. Watch for the successor announcement and any strategic shifts under new financial leadership.
At the time of this announcement, KMDA was trading at $7.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $409.1M. The 52-week trading range was $6.50 to $9.35. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.